MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
4.530
+0.290
+6.84%
After Hours: 4.520 -0.01 -0.22% 19:43 05/22 EDT
OPEN
4.460
PREV CLOSE
4.240
HIGH
4.640
LOW
4.360
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
4.640
52 WEEK LOW
1.185
MARKET CAP
287.94M
P/E (TTM)
-4.0748
1D
5D
1M
3M
1Y
5Y
1D
MacroGenics Shareholders Back Board, Auditors and Equity Plan
TipRanks · 3d ago
MacroGenics shareholders approved 1.25 million-share increase to 2023 equity plan
PUBT · 3d ago
Weekly Report: what happened at MGNX last week (0511-0515)?
Weekly Report · 6d ago
MacroGenics (MGNX) Quarterly Loss Of US$36.8 Million Tests Bullish Path To Profitability
Simply Wall St · 05/14 23:30
Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (CLPT), Rapid Micro Biosystems (RPID) and MacroGenics (MGNX)
TipRanks · 05/14 13:11
Barclays Reaffirms Their Buy Rating on MacroGenics (MGNX)
TipRanks · 05/14 09:25
Macrogenics Q1 EPS $(0.58) Beats $(0.65) Estimate, Sales $20.775M Beat $15.050M Estimate
Benzinga · 05/13 20:56
MacroGenics Q1 revenue rises, beats estimates on client production and cancer drug royalties  
Reuters · 05/13 20:13
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

Webull offers MacroGenics Inc stock information, including NASDAQ: MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.